Replies to post #179093 on Biotech Values

[genisi]

Thanks for the link.

[zipjet]

RCPT

Slide 7* confirms that Tysabri is the BIC for reducing relapses in RRMS with a 67% reduction.

On Tysabri my wife went about 5 years without an attack or any evidence of new injury per gd-MRI. (Switched her to Tecfidera due to JCV+)




* RMS Clinical Efficacy Outcomes
Comparison of Reduction in Annualized Relapse Rate (ARR)

[DewDiligence]

RCPT selling unspecified number of shares at unspecified price in underwritten offering:

http://finance.yahoo.com/news/receptos-announces-proposed-underwritten-public-200849419.html

The share price is +31% since the 6/9/14 announcement on the phase-2 portion of the clinical trial in MS (#msg-103084060).

[DewDiligence]

RCPT sells 5.1M* shares @40.25, a 2% discount to yesterday’s close:

http://finance.yahoo.com/news/receptos-announces-pricing-underwritten-public-234230954.html

*Assuming exercise of underwriter’s option.

[jq1234]

RCPT RPC1063 in RRMS ph2 RADIANCE Detailed Results:

Very impressive overall: http://edge.media-server.com/m/p/d7ijijuy/?token=khj3d3bp171qj5lskwx4qwoey6pspxc5fntmk8mg7v316ude2874450